[{"orgOrder":0,"company":"Mayne Pharma Do Brasil Ltda","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"BRAZIL","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Itraconazole","moa":"Cytochrome P450 51","graph1":"Hematology","graph2":"Phase IV","graph3":"Mayne Pharma Do Brasil Ltda","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mayne Pharma Do Brasil Ltda \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mayne Pharma Do Brasil Ltda \/ Undisclosed"},{"orgOrder":0,"company":"Mayne Pharma Do Brasil Ltda","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"BRAZIL","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Itraconazole","moa":"Cytochrome P450 51","graph1":"Hematology","graph2":"Phase IV","graph3":"Mayne Pharma Do Brasil Ltda","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mayne Pharma Do Brasil Ltda \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mayne Pharma Do Brasil Ltda \/ Undisclosed"},{"orgOrder":0,"company":"Mayne Pharma Do Brasil Ltda","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Steroid","year":"2019","type":"Inapplicable","leadProduct":"Halobetasol","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Mayne Pharma Do Brasil Ltda","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Mayne Pharma Do Brasil Ltda \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mayne Pharma Do Brasil Ltda \/ Undisclosed"},{"orgOrder":0,"company":"Mayne Pharma Do Brasil Ltda","sponsor":"Biorasi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Glutamate-gated chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mayne Pharma Do Brasil Ltda","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Mayne Pharma Do Brasil Ltda \/ Biorasi","highestDevelopmentStatusID":"10","companyTruncated":"Mayne Pharma Do Brasil Ltda \/ Biorasi"},{"orgOrder":0,"company":"Mayne Pharma Do Brasil Ltda","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Trifarotene","moa":"Retinoic acid receptor gamma","graph1":"Dermatology","graph2":"Phase II","graph3":"Mayne Pharma Do Brasil Ltda","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Mayne Pharma Do Brasil Ltda \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mayne Pharma Do Brasil Ltda \/ Undisclosed"},{"orgOrder":0,"company":"Mayne Pharma Do Brasil Ltda","sponsor":"Mayne Pharma Do Brasil Ltda","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Mayne Pharma Do Brasil Ltda","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Mayne Pharma Do Brasil Ltda \/ Mayne Pharma Do Brasil Ltda","highestDevelopmentStatusID":"6","companyTruncated":"Mayne Pharma Do Brasil Ltda \/ Mayne Pharma Do Brasil Ltda"},{"orgOrder":0,"company":"Mayne Pharma Do Brasil Ltda","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Mayne Pharma Do Brasil Ltda","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Mayne Pharma Do Brasil Ltda \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"Mayne Pharma Do Brasil Ltda \/ GSK"},{"orgOrder":0,"company":"Mayne Pharma Do Brasil Ltda","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Mayne Pharma Do Brasil Ltda","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Mayne Pharma Do Brasil Ltda \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"Mayne Pharma Do Brasil Ltda \/ GSK"},{"orgOrder":0,"company":"Mayne Pharma Do Brasil Ltda","sponsor":"Biorasi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Permethrin","moa":"Voltage-sensitive sodium channel","graph1":"Dermatology","graph2":"Phase III","graph3":"Mayne Pharma Do Brasil Ltda","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Mayne Pharma Do Brasil Ltda \/ Biorasi","highestDevelopmentStatusID":"10","companyTruncated":"Mayne Pharma Do Brasil Ltda \/ Biorasi"},{"orgOrder":0,"company":"Mayne Pharma Do Brasil Ltda","sponsor":"George R Thompson","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Itraconazole","moa":"Cytochrome P450 51","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Mayne Pharma Do Brasil Ltda","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mayne Pharma Do Brasil Ltda \/ George R Thompson","highestDevelopmentStatusID":"8","companyTruncated":"Mayne Pharma Do Brasil Ltda \/ George R Thompson"},{"orgOrder":0,"company":"Mayne Pharma Do Brasil Ltda","sponsor":"M. Eugenia Socias","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"BRAZIL","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Morphine Sulfate","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Mayne Pharma Do Brasil Ltda","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayne Pharma Do Brasil Ltda \/ M. Eugenia Socias","highestDevelopmentStatusID":"10","companyTruncated":"Mayne Pharma Do Brasil Ltda \/ M. Eugenia Socias"}]

Find Clinical Drug Pipeline Developments & Deals by LIBBS FARMO QUIMICA LTDA

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Itraconazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Coccidioidomycosis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 22, 2021

                          Lead Product(s) : Itraconazole

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : George R Thompson

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Calcipotriene is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Keratosis, Actinic.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 24, 2019

                          Lead Product(s) : Calcipotriol

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase I

                          Recipient : Tulane University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Halobetasol Propionate is a Steroid drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Psoriasis.

                          Product Name : Undisclosed

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          June 20, 2019

                          Lead Product(s) : Halobetasol

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Morphine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Opioid-Related Disorders.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 14, 2019

                          Lead Product(s) : Morphine Sulfate

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : M. Eugenia Socias

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Trifarotene is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Ichthyosis, Lamellar.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 13, 2018

                          Lead Product(s) : Trifarotene

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Ivermectin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pediculus.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 09, 2017

                          Lead Product(s) : Ivermectin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Biorasi

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Permethrin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Scabies.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 01, 2016

                          Lead Product(s) : Permethrin

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Biorasi

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Itraconazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neutropenia.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 29, 2016

                          Lead Product(s) : Itraconazole

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Itraconazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Neutropenia.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 04, 2015

                          Lead Product(s) : Itraconazole

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Calcipotriene is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Psoriasis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 23, 2012

                          Lead Product(s) : Calcipotriol

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase I

                          Sponsor : GSK

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank